1,217 Shares in Cencora, Inc. (NYSE:COR) Bought by Miracle Mile Advisors LLC

Miracle Mile Advisors LLC bought a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,217 shares of the company's stock, valued at approximately $273,000.

Other large investors also recently added to or reduced their stakes in the company. Concord Wealth Partners purchased a new stake in Cencora during the 3rd quarter worth approximately $30,000. SYSTM Wealth Solutions LLC purchased a new stake in shares of Cencora during the second quarter worth about $36,000. Ashton Thomas Securities LLC purchased a new position in shares of Cencora in the third quarter valued at approximately $41,000. Fairscale Capital LLC acquired a new stake in shares of Cencora in the second quarter worth approximately $54,000. Finally, Modus Advisors LLC purchased a new stake in shares of Cencora during the fourth quarter worth approximately $54,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Trading Up 0.5 %

NYSE:COR traded up $1.22 on Friday, reaching $242.11. 1,492,996 shares of the company's stock were exchanged, compared to its average volume of 1,280,308. The firm has a market capitalization of $46.80 billion, a price-to-earnings ratio of 32.24, a price-to-earnings-growth ratio of 1.48 and a beta of 0.49. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $253.27. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The business has a fifty day moving average of $237.65 and a 200-day moving average of $233.72.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, November 15th. This is a positive change from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a yield of 0.91%. Cencora's dividend payout ratio is 29.29%.

Wall Street Analysts Forecast Growth

COR has been the topic of a number of recent research reports. Barclays boosted their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Evercore ISI increased their price target on Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Finally, Mizuho began coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective for the company. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $275.60.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares of the company's stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. The trade was a 7.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 94,696 shares of company stock valued at $22,862,734 in the last 90 days. Company insiders own 15.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.